A national analysis of bowel surveillance for people with inflammatory bowel disease has identified practical differences in how the examinations are delivered that are associated with finding polyps—small growths that can sometimes become cancer.
The study, led by the University of Edinburgh and published in the Journal of Crohn’s and Colitis, examined almost 16,000 procedures performed in 2024. Its authors say the findings offer a starting point for making surveillance more consistent for patients with inflammatory bowel disease, or IBD.
Why surveillance matters
People whose IBD affects the large bowel, including some people with Crohn’s disease and ulcerative colitis, face an elevated risk of bowel cancer. Regular endoscopic checks allow clinicians to inspect the bowel with a camera and look for early changes.
In practice, those surveillance procedures are commonly scheduled alongside other hospital endoscopy work. That can make it difficult to provide a uniform approach across services, despite the specialist nature of the examination.
The new research is described as the first UK-wide, national-scale assessment of the quality of IBD endoscopies. It draws on the National Endoscopy Database, which covers about 65% of UK endoscopy units.
What the researchers found
The database contained procedures undertaken by 4,669 endoscopists. Fewer than one in five of those clinicians performed IBD surveillance checks at least once a month. That smaller group nevertheless carried out 57% of the procedures included in the analysis.
Three characteristics were associated with polyp detection: the experience of the professional conducting the check, the amount of time available for the procedure and use of a special dye to improve visibility.
The relationship is important because a polyp found during surveillance can be assessed and, where appropriate, removed or followed up. The study does not establish that changing any one of these factors will reduce cancer rates, but it does identify measurable parts of care that could be studied and improved.
Implications for services
The authors say the results support further investigation of more consistent pathways and protected time for IBD surveillance. A service model that ensures regular exposure to these procedures, adequate appointment time and appropriate visualisation techniques could make care less variable between sites and clinicians.
That does not mean every patient should assume that a short appointment or a less frequent operator is unsafe. The study reports associations across a large real-world dataset; it does not provide an individual prediction of cancer risk or prescribe a single clinical pathway. Decisions on surveillance remain dependent on a patient’s condition and clinical team.
Still, the scale of the dataset makes the findings useful for quality improvement. Rather than treating surveillance simply as another routine endoscopy slot, providers can examine whether specialist experience and procedure design are being given enough weight in scheduling and workforce planning.
What the study cannot yet answer
The National Endoscopy Database did not contain laboratory results for removed polyps. As a result, the researchers could not determine whether the differences in detection translated into finding fewer cancers or more clinically significant precancerous changes.
Further work will be needed to identify which operational changes produce the best patient outcomes and whether they can be deployed consistently across the health system. But the analysis provides evidence that how an IBD surveillance examination is organised is linked with what it detects.
For a population already monitored because of heightened bowel-cancer risk, that is a meaningful signal. It shifts the discussion from whether surveillance should occur to how it can be delivered with the most reliable chance of identifying early changes.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
